Evidence map›Paper›PMID 29717011›Full record

ArticlemBio2018

Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.

Punya Shrivastava-Ranjan, Mike Flint, Éric Bergeron, Anita K McElroy, Payel Chatterjee, César G Albariño, Stuart T Nichol, Christina F Spiropoulou

Open access · goldAbstract read
In one paragraph

Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Host centric drug repurposing for viral diseases.PLoS computational biology · 2025
    Article
  4. Statins, Allies against Antibiotic Resistance?Current medicinal chemistry · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Statins: Beneficial Effects in Treatment of COVID-19.Advances in experimental medicine and biology · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. The role of lovastatin in the attenuation of COVID-19.International immunopharmacology · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Punya Shrivastava-RanjanViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mike FlintViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Éric BergeronViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-3398-8628
Anita K McElroyViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Payel ChatterjeeViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
César G AlbariñoViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Stuart T NicholViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Christina F SpiropoulouViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA ccs8@cdc.gov.
Centers for Disease Control and Prevention · US

Funding

Immune correlates of protection from Rift Valley fever virusK08AI119448 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MCELROY, ANITA K · 2016 to 2019
$713k
NIAID NIH HHS K08 AI119448
6 · The paper itself

Abstract

Ebola virus (EBOV) infection is a major public health concern due to high fatality rates and limited effective treatments. Statins, widely used cholesterol-lowering drugs, have pleiotropic mechanisms of action and were suggested as potential adjunct therapy for Ebola virus disease (EVD) during the 2013-2016 outbreak in West Africa. Here, we evaluated the antiviral effects of statin (lovastatin) on EBOV infection

Indexed as

Antiviral AgentsCell LineEbolavirusHemorrhagic Fever, EbolaHumansHydroxymethylglutaryl-CoA Reductase InhibitorsProtein Processing, Post-TranslationalViral Envelope ProteinsVirulenceVirus InternalizationAntiviral AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsViral Envelope ProteinsantiviralEbola virusFiloviridaehemorrhagic fever

Identifiers

PMID29717011
PMCPMC5930306
OpenAlexW2801251501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.